Indian Firms Look To Cash In On Growing Demand For Biosimilars

NEW DELHI - Increasing interest in the European Union and U.S. for biosimilar drugs has prompted Indian companies to actively explore these markets. Various estimates have predicted that the market for biosimilars could increase to $25 billion in Europe and $30 billion in the U.S. by 2015. Indian companies are looking to exploit such opportunities